Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 3/20 | 0.31 |
| ▸ | ABL1 | P00519 | 3/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.31 |
| ▸ | RET | P07949 | 3/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.31 |
| ▸ | BCR | P11274 | 2/20 | 0.31 |
| ▸ | PLK4 | O00444 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387209 | 0.88 | ALDH1A1 (0.37) | CDK2CCNA2CCNA1PHGDHKMT2A | |
| SCHEMBL2386658 | 0.86 | PHGDH (0.44) | CDK2CCNA2CCNA1PHGDHPDE4A | |
| SCHEMBL2387205 | 0.75 | CCNA2 (0.44) | CDK2CCNA2CCNA1PHGDHPDE4A | |
| SCHEMBL2386081 | 0.72 | PDE10A (0.38) | PDE4A | |
| SCHEMBL2387658 | 0.71 | HIF1A (0.50) | MAPK1KMT2AALDH1A1 | |
| SCHEMBL2386408 | 0.71 | CCNA2 (0.40) | CDK2CCNA2CCNA1PHGDHPDE4A | |
| SCHEMBL15668408 | 0.70 | ALDH1A1 (0.55) | ALDH1A1 | |
| SCHEMBL25276232 | 0.69 | APEX1 (0.41) | LCKFYNKMT2AALDH1A1 | |
| SCHEMBL12273046 | 0.69 | ALDH1A1 (0.37) | CDK2CCNA2CCNA1MAPK1ALDH1A1 | |
| SCHEMBL15668315 | 0.69 | KDM4E (0.50) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9102643-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150133675-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2015-05-14 | — | — | US | disclosed |
| US-20140228581-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | PDE10A, PDE9A, PDE7A | CDK2 1082/4885CCNA2 3770/4885CCNA1 3884/4885 |
| US-20140228581-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | CDK2 1082/4885CCNA2 3770/4885CCNA1 3884/4885 |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | CDK2 1082/4885CCNA2 3770/4885CCNA1 3884/4885 |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | CDK2 1082/4885CCNA2 3770/4885CCNA1 3884/4885 |
| US-20150133675-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | CDK2 1082/4885CCNA2 3770/4885CCNA1 3884/4885 |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | CDK2 1082/4885CCNA2 3770/4885CCNA1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.